Corixa to Present at Nomura and BIO CEO Conferences in February.Business Editors/Health/Medical Writers BIOWIRE2K BIO CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. & Investor Conference 2003 SEATTLE--(BUSINESS WIRE)--Feb. 12, 2003 Corixa Corporation (Nasdaq:CRXA), a developer of immunotherapeutics, announced today that David Fanning David Fanning may refer to:
The officer of a firm responsible for day-to-day management, usually the president or an executive vice-president. , will provide an overview of company programs at the sixth Annual Nomura Bioconference on February 13, 2002. The conference will be held at the Akasaka Prince Hotel in Tokyo, Japan. On February 27 at 12:00 pm ET, Steven Gillis, chairman and chief executive officer at Corixa will provide a program update at the fifth annual BIO CEO and Investor Conference at the Waldorf Astoria Hotel in New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. . A link to a live audio webcast of the presentation can be accessed from the Investors section of Corixa's website (http://www.corixa.com/default.asp?pid=invest). A recorded replay of the webcast will be available for 90 days after the event, via the website. About Corixa Corixa is a developer of immunotherapeutics with a commitment to treating and preventing autoimmune diseases Autoimmune diseases A group of diseases, like rheumatoid arthritis and systemic lupus erythematosus, in which immune cells turn on the body, attacking various tissues and organs. Mentioned in: Complement Deficiencies, Premature Menopause , cancer and infectious diseases by understanding and directing the immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. . Corixa is focused on immunotherapeutic products and has a broad technology platform enabling both fully integrated vaccine design and the use of its separate, proprietary product components on a standalone basis. Corixa currently has multiple programs in clinical development, including several product candidates that have advanced to or through late stage clinical trials. The company partners with numerous developers and marketers of pharmaceuticals, targeting products that are Powered by Corixa(TM) technology with the goal of making its potential products available to patients around the world. Corixa was founded in 1994 and is headquartered in Seattle, with additional operations in Hamilton, Mont., and South San Francisco South San Francisco, city (1990 pop. 54,312), San Mateo co., W Calif.; inc. 1908. South San Francisco has several industrial parks; its manufactures include medical supplies and equipment, foods, paint, paper products, consumer goods, and clothing. . For more information, please visit Corixa's Web site at www.corixa.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion